{"paper_id": "17e65e5ee1427a61375b03b51013d7e1b4cf9bdd", "metadata": {"title": "", "authors": []}, "abstract": [], "body_text": [{"text": "Supplementary ", "cite_spans": [], "ref_spans": [], "section": "Supplementary Tables"}, {"text": "Cruz-Valdez *This trial compared adjuvanted and non-adjuvanted vaccine formulations with unequal hemagglutinin antigen dose. The hemagglutinin antigen dose was reduced in the adjuvanted arm (antigen-sparing design). \u2020This trial compared adjuvanted influenza vaccines and non-adjuvanted influenza vaccines from different manufacturers.", "cite_spans": [], "ref_spans": [], "section": "Follow-up time Results"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant", "authors": [{"first": "T", "middle": [], "last": "Vesikari", "suffix": ""}, {"first": "M", "middle": [], "last": "Pellegrini", "suffix": ""}, {"first": "A", "middle": [], "last": "Karvonen", "suffix": ""}], "year": 2009, "venue": "Pediatr Infect Dis J", "volume": "28", "issn": "7", "pages": "563--571", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination", "authors": [{"first": "T", "middle": [], "last": "Vesikari", "suffix": ""}, {"first": "N", "middle": [], "last": "Groth", "suffix": ""}, {"first": "A", "middle": [], "last": "Karvonen", "suffix": ""}, {"first": "A", "middle": [], "last": "Borkowski", "suffix": ""}, {"first": "M", "middle": [], "last": "Pellegrini", "suffix": ""}], "year": 2009, "venue": "Vaccine", "volume": "27", "issn": "45", "pages": "6291--6295", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age", "authors": [{"first": "A", "middle": [], "last": "Arguedas", "suffix": ""}, {"first": "C", "middle": [], "last": "Soley", "suffix": ""}, {"first": "A", "middle": [], "last": "Abdelnour", "suffix": ""}], "year": 2011, "venue": "Hum Vaccin", "volume": "7", "issn": "1", "pages": "58--66", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Trivalent and quadrivalent MF59-adjuvanted influenza vaccine in young children: a dose-and schedule-finding study", "authors": [{"first": "Della", "middle": [], "last": "Cioppa", "suffix": ""}, {"first": "G", "middle": [], "last": "Vesikari", "suffix": ""}, {"first": "T", "middle": [], "last": "Sokal", "suffix": ""}, {"first": "E", "middle": [], "last": "Lindert", "suffix": ""}, {"first": "K", "middle": [], "last": "Nicolay", "suffix": ""}, {"first": "U", "middle": [], "last": "", "suffix": ""}], "year": 2011, "venue": "Vaccine", "volume": "29", "issn": "47", "pages": "8696--8704", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Oil-in-water emulsion adjuvant with influenza vaccine in young children", "authors": [{"first": "T", "middle": [], "last": "Vesikari", "suffix": ""}, {"first": "M", "middle": [], "last": "Knuf", "suffix": ""}, {"first": "P", "middle": [], "last": "Wutzler", "suffix": ""}], "year": 2011, "venue": "N Eng J Med", "volume": "365", "issn": "15", "pages": "1406--1416", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six-to less than thirty-six-month-old children", "authors": [{"first": "S", "middle": ["L"], "last": "Block", "suffix": ""}, {"first": "G", "middle": ["M"], "last": "Ruiz-Palacios", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Guerrero", "suffix": ""}, {"first": "J", "middle": [], "last": "Beygo", "suffix": ""}, {"first": "V", "middle": [], "last": "Sales", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Holmes", "suffix": ""}], "year": 2012, "venue": "Pediatr Infect Dis J", "volume": "31", "issn": "7", "pages": "92--98", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity", "authors": [{"first": "J", "middle": ["M"], "last": "Langley", "suffix": ""}, {"first": "D", "middle": [], "last": "Reich", "suffix": ""}, {"first": "N", "middle": [], "last": "Aggarwal", "suffix": ""}], "year": 2012, "venue": "Pediatr Infect Dis J", "volume": "31", "issn": "8", "pages": "848--858", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age", "authors": [{"first": "C", "middle": [], "last": "Nassim", "suffix": ""}, {"first": "S", "middle": [], "last": "Christensen", "suffix": ""}, {"first": "D", "middle": [], "last": "Henry", "suffix": ""}, {"first": "S", "middle": [], "last": "Holmes", "suffix": ""}, {"first": "M", "middle": [], "last": "Hohenboken", "suffix": ""}, {"first": "N", "middle": [], "last": "Kanesa-Thasan", "suffix": ""}], "year": 2012, "venue": "Pediatr Infect Dis J", "volume": "31", "issn": "4", "pages": "59--65", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children", "authors": [{"first": "T", "middle": [], "last": "Nolan", "suffix": ""}, {"first": "L", "middle": [], "last": "Bravo", "suffix": ""}, {"first": "A", "middle": [], "last": "Ceballos", "suffix": ""}], "year": 2014, "venue": "Vaccine", "volume": "32", "issn": "46", "pages": "6146--6156", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial", "authors": [{"first": "T", "middle": [], "last": "Nolan", "suffix": ""}, {"first": "S", "middle": [], "last": "Roy-Ghanta", "suffix": ""}, {"first": "M", "middle": [], "last": "Montellano", "suffix": ""}], "year": 2014, "venue": "J Infect Dis", "volume": "210", "issn": "4", "pages": "545--557", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "Immunogenicity and safety of cell-derived MF59-adjuvanted A/H1N1 influenza vaccine for children", "authors": [{"first": "M", "middle": [], "last": "Knuf", "suffix": ""}, {"first": "G", "middle": [], "last": "Leroux-Roels", "suffix": ""}, {"first": "H", "middle": [], "last": "Rumke", "suffix": ""}], "year": 2015, "venue": "Hum Vaccin Immunother", "volume": "11", "issn": "2", "pages": "358--376", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children", "authors": [{"first": "A", "middle": ["R"], "last": "Solares", "suffix": ""}, {"first": "C", "middle": ["G"], "last": "Aragon", "suffix": ""}, {"first": "R", "middle": ["U"], "last": "Pivaral", "suffix": ""}], "year": 2014, "venue": "J Infect Dev Ctries", "volume": "8", "issn": "9", "pages": "1160--1168", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine", "authors": [{"first": "T", "middle": [], "last": "Vesikari", "suffix": ""}, {"first": "A", "middle": [], "last": "Forsten", "suffix": ""}, {"first": "A", "middle": [], "last": "Arora", "suffix": ""}, {"first": "T", "middle": [], "last": "Tsai", "suffix": ""}, {"first": "R", "middle": [], "last": "Clemens", "suffix": ""}], "year": 2015, "venue": "Hum Vaccin Immunother", "volume": "11", "issn": "8", "pages": "2102--2112", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age", "authors": [{"first": "L", "middle": [], "last": "Zedda", "suffix": ""}, {"first": "E", "middle": [], "last": "Forleo-Neto", "suffix": ""}, {"first": "A", "middle": [], "last": "Vertruyen", "suffix": ""}], "year": 2015, "venue": "Pediatr Infect Dis J", "volume": "34", "issn": "1", "pages": "73--78", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial", "authors": [{"first": "T", "middle": [], "last": "Vesikari", "suffix": ""}, {"first": "J", "middle": [], "last": "Kirstein", "suffix": ""}, {"first": "Devota", "middle": [], "last": "Go", "suffix": ""}, {"first": "G", "middle": [], "last": "", "suffix": ""}], "year": 2018, "venue": "Lancet Respir Med", "volume": "6", "issn": "5", "pages": "345--356", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "MF59-adjuvanted influenza vaccine (FLUAD) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone): A randomized, multicenter, Phase III pediatric trial in Mexico", "authors": [{"first": "A", "middle": [], "last": "Cruz-Valdez", "suffix": ""}, {"first": "G", "middle": [], "last": "Valdez-Zapata", "suffix": ""}, {"first": "S", "middle": ["S"], "last": "Patel", "suffix": ""}], "year": 2018, "venue": "Hum Vaccin Immunother", "volume": "14", "issn": "2", "pages": "386--395", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-na\u00efve children in a randomized clinical trial in rural Senegal", "authors": [{"first": "A", "middle": [], "last": "Diallo", "suffix": ""}], "year": 2018, "venue": "Vaccine", "volume": "36", "issn": "", "pages": "6424--6432", "other_ids": {}}, "BIBREF17": {"ref_id": "b17", "title": "Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study", "authors": [{"first": "C", "middle": ["S"], "last": "Waddington", "suffix": ""}, {"first": "W", "middle": ["T"], "last": "Walker", "suffix": ""}, {"first": "C", "middle": [], "last": "Oeser", "suffix": ""}], "year": 2010, "venue": "BMJ", "volume": "340", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "showing the ratios of the seroprotection rate (SPR) against H1N1, defined as a \u22651:40 haemagglutinin-inhibition (HI) titer, 21-28 days after the second dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 2. Meta-regression showing a linear relationship (slope = 0.98, P <0.001) between the ratios of seroprotection rates against H1N1 after the second dose and the inverse of seroprotection rate in non-adjuvanted arm, with an R 2 of 95.47% Supplementary Figure 3. Forest plot showing the ratios of the seroprotection rate (SPR) against H3N2, defined as a \u22651:40 haemagglutinin-inhibition (HI) titer, 21-28 days after the second dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 4. Meta-regression showing a linear relationship (slope = 0.91, P <0.001) between the ratios of seroprotection rates against H3N2 after the second dose and the inverse of seroprotection rate in non-adjuvanted arm, with an R 2 of 88.92% Supplementary Figure 5. Forest plot showing the ratios of the seroprotection rate (SPR) against influenza B, defined as a \u22651:40 haemagglutinininhibition (HI) titer, 21-28 days after the first dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 6. Forest plot showing the risk ratios of pain/tenderness at the injection site during the 7 days after the first dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 7. Forest plot showing the risk ratios of fever during the 7 days after the first dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 8. Forest plot showing the risk ratios of pain/tenderness at the injection site during the 7 days after the second dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Forest plot showing the risk ratios of fever during the 7 days after the second dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 10. Funnel plot with pseudo 95% confidence limits. Sensitivity analysis by excluding Langley (2012): forest plot showing the ratios of the seroprotection rate (SPR) against H1N1, defined as a \u22651:40 haemagglutinin-inhibition (HI) titer, 21-28 days after the first dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 14. Sensitivity analysis by excluding Langley (2012): metaregression showing a linear relationship (slope = 0.79, P <0.001) between the ratios of seroprotection rates against H1N1 after the first dose and the inverse of seroprotection rate in nonadjuvanted arm, with an R 2 of 99.81%. Supplementary Figure 15. Sensitivity analysis by excluding Zedda (2015): forest plot showing the ratios of the seroprotection rate (SPR) against H3N2, defined as a \u22651:40 haemagglutinin-inhibition (HI) titer, 21-28 days after the second dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 16. Sensitivity analysis by excluding Zedda (2015): meta-regression showing a linear relationship (slope = 0.91, P <0.001) between the ratios of seroprotection rates against H3N2 after the second dose and the inverse of seroprotection rate in non-adjuvanted arm, with an R 2 of 88.54%. Supplementary Figure 17. Sensitivity analysis by excluding Zedda (2015): forest plot showing the ratios of the seroprotection rate (SPR) against influenza B, defined as a \u22651:40 haemagglutinin-inhibition (HI) titer, 21-28 days after the second dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 18. Sensitivity analysis by excluding Zedda (2015): meta-regression showing a linear relationship (slope = 0.88, P <0.001) between the ratios of seroprotection rates against influenza B after the second dose and the inverse of seroprotection rate in nonadjuvanted arm, with an R 2 of 99.63%. Supplementary Figure 19. Sensitivity analysis by excluding the 12 trials which did not compare the same vaccine with or without adjuvants (using adjuvanted and non-adjuvanted vaccines from different manufacturers, or using antigen-sparing design with reduced antigen dose in adjuvanted vaccines): forest plot showing the risk ratios of RT-PCR-confirmed influenza among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 20. Sensitivity analysis by excluding the 12 trials which did not compare the same vaccine with or without adjuvants (using adjuvanted and non-adjuvanted vaccines from different manufacturers, or using antigen-sparing design with reduced antigen dose in adjuvanted vaccines): forest plot showing the ratios of the seroprotection rate (SPR) against H1N1, defined as a \u22651:40 haemagglutinin-inhibition (HI) titer, 21-28 days after the first dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 21. Sensitivity analysis by excluding the 12 trials which did not compare the same vaccine with or without adjuvants (using adjuvanted and non-adjuvanted vaccines from different manufacturers, or using antigen-sparing design with reduced antigen dose in adjuvanted vaccines): meta-regression showing a linear relationship (slope = 0.90, P <0.001) between the ratios of the seroprotection rate against H1N1 after the first dose and the inverse of seroprotection rate in non-adjuvanted arm, with an R 2 of 99.56%. Supplementary Figure 22. Sensitivity analysis by excluding the 12 trials which did not compare the same vaccine with or without adjuvants (using adjuvanted and non-adjuvanted vaccines from different manufacturers, or using antigen-sparing design with reduced antigen dose in adjuvanted vaccines): forest plot showing the ratios of the seroprotection rate (SPR) against H3N2, defined as a \u22651:40 haemagglutinin-inhibition (HI) titer, 21-28 days after the first dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 23. Sensitivity analysis by excluding the 12 trials which did not compare the same vaccine with or without adjuvants (using adjuvanted and non-adjuvanted vaccines from different manufacturers, or using antigen-sparing design with reduced antigen dose in adjuvanted vaccines): meta-regression showing a linear relationship (slope = 0.95, P <0.001) between the ratios of the seroprotection rate against H3N2 after the first dose and the inverse of seroprotection rate in non-adjuvanted arm, with an R 2 of 100%. Supplementary Figure 24. Sensitivity analysis by excluding the 12 trials which did not compare the same vaccine with or without adjuvants (using adjuvanted and non-adjuvanted vaccines from different manufacturers, or using antigen-sparing design with reduced antigen dose in adjuvanted vaccines): forest plot showing the ratios of the seroprotection rate (SPR) against influenza B, defined as a \u22651:40 haemagglutinin-inhibition (HI) titer, 21-28 days after the second dose among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 25. Sensitivity analysis by excluding the 12 trials which did not compare the same vaccine with or without adjuvants (using adjuvanted and non-adjuvanted vaccines from different manufacturers, or using antigen-sparing design with reduced antigen dose in adjuvanted vaccines): meta-regression showing a linear relationship (slope=0.83, p<0.001) between the ratios of the seroprotection rate against influenza B after the second dose and the inverse of seroprotection rate in non-adjuvanted arm, with an R 2 of 99.84%. Supplementary Figure 26. Sensitivity analysis by excluding the 12 trials which did not compare the same vaccine with or without adjuvants (using adjuvanted and non-adjuvanted vaccines from different manufacturers, or using antigen-sparing design with reduced antigen dose in adjuvanted vaccines): forest plot showing the risk ratios of serious adverse events during the follow-up time after the vaccinations among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 27. Sensitivity analysis by excluding the 12 trials which did not compare the same vaccine with or without adjuvants (using adjuvanted and non-adjuvanted vaccines from different manufacturers, or using antigen-sparing design with reduced antigen dose in adjuvanted vaccines): forest plot showing the risk ratios of neurological events during the follow-up time after the vaccinations among children who received adjuvanted versus non-adjuvanted trivalent vaccines (TIV) or quadrivalent vaccines (QIV). Supplementary Figure 28. Sensitivity analysis by excluding 2 data points (both reported in Diallo 2018) with an inverse of seroprotection rate in nonadjuvanted arm larger than 5: Meta-regression still showed a linear relationship (slope = 0.90, P <0.001) between the ratios of seroprotection rates against H1N1 after the first dose and the inverse of seroprotection rate in non-adjuvanted arm, with an R 2 of 98.67%. Supplementary Figure 29. Sensitivity analysis by excluding 2 data points (Vesikari 2011 and Della Cioppa 2011) with an inverse of seroprotection rate in non-adjuvanted arm larger than 5: Meta-regression results became imprecise (slope = 0.47, P=0.075) between the ratios of seroprotection rates against H3N2 after the first dose and the inverse of seroprotection rate in non-adjuvanted arm, with an R 2 of 42.98%, after the sample size decreased to only seven. Supplementary Figure 30. Sensitivity analysis by excluding 2 data points (Vesikari 2011 and Della Cioppa 2011), with an inverse of seroprotection rate in non-adjuvanted arm larger than 5: Meta-regression still showed a linear relationship (slope = 0.86, P <0.001) between the ratios of seroprotection rates against influenza B after the first dose and the inverse of seroprotection rate in nonadjuvanted arm, with an R 2 of 96.21%.", "latex": null, "type": "figure"}, "FIGREF1": {"text": "adjuvant* OR MF59 OR AS03) AND (influenza vaccin*) AND (influenza or flu*) AND (vaccin* OR immun* OR inocul*) AND (child* OR infant* OR toddler* OR pediatric* OR pacdiatric*) Supplementary Note 5. Google Scholar strategy (adjuvant* OR MF59 OR AS03) AND (influenza vaccin*) AND (influenza or flu*) AND (vaccin* OR immun* OR inocul*) AND (child* OR infant* OR toddler* OR pediatric* OR paediatric*) -avian -adult -elderly -animal -cell Supplementary Note 6. WHO ICTRP (Search for clinical trials in children), Grey Literature Report, Open Grey, RePORT, HSRProj, AHRQ Grants On-Line Database, HSRR search strategy (Vaccine* AND influenza) AND (adjuvant* OR MF59 OR AS03) (immuni* AND influenza) AND (adjuvant* OR MF59 OR AS03) (inocul* AND influenza) AND (adjuvant* OR MF59 OR AS03) (vaccine* AND flu) AND (adjuvant* OR MF59 OR AS03) (immuni* AND flu) AND (adjuvant* OR MF59 OR AS03) (inocul* AND flu) AND (adjuvant* OR MF59 OR AS03)", "latex": null, "type": "figure"}, "FIGREF2": {"text": "This trial compared adjuvanted and non-adjuvanted vaccine formulations with unequal hemagglutinin antigen dose. The hemagglutinin antigen dose was reduced in the adjuvanted arm (antigen-sparing design). \u2020This trial compared adjuvanted influenza vaccines and non-adjuvanted influenza vaccines from different manufacturers. 32 Supplementary", "latex": null, "type": "figure"}, "TABREF0": {"text": "Randomized controlled trials that reported efficacy data Supplementary Table 2. Randomized controlled trials that reported seroprotection data Supplementary Table 3. Randomized controlled trials that reported serious adverse events Supplementary Table 4. Randomized controlled trials that reported neurological events Supplementary Table 5. Randomized controlled trials that reported reactogenicity data Supplementary Table 6. Summary of findings: certainty of evidence for effect outcomes Supplementary Table 7. Summary of findings: certainty of evidence for harm outcomes", "latex": null, "type": "table"}, "TABREF2": {"text": "Supplementary Note 7. Clinical Trials.gov search strategy (adjuvant OR MF59 OR AS03) AND (influenza vaccine) AND (vaccination OR immunizationOR inoculation) AND (child OR infant OR toddler OR pediatric OR paediatric)Supplementary Note 8. List of excluded studies and the reasons for exclusionNot trials that compared adjuvanted vs. non-adjuvanted vaccines Thebault 2015 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Vesikari 2015 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Hoschler 2014 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Not trials that compared adjuvanted vs. non-adjuvanted vaccines Not trials that compared adjuvanted vs. non-adjuvanted vaccines Nohynek 2012 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Not trials that compared adjuvanted vs. non-adjuvanted vaccines Banzhoff 2011 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Bardage 2011 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Not trials that compared adjuvanted vs. non-adjuvanted vaccines Gilca 2011 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Griffin 2011 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Kries 2011 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Ortqvist 2011 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Parretta 2011 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Scheifele 2011 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Sicilia 2011 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Not trials that compared adjuvanted vs. non-adjuvanted vaccines Uphoff 2011 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Not trials that compared adjuvanted vs. non-adjuvanted vaccines Not trials that compared adjuvanted vs. non-adjuvanted vaccines Marchetti 2007 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Woodhour 1969 Not trials that compared adjuvanted vs. non-adjuvanted vaccines Supplementary Table 1. Randomized controlled trials that reported efficacy data against RT-PCR confirmed influenza *This trial compared adjuvanted and non-adjuvanted vaccine formulations with unequal hemagglutinin antigen dose. The hemagglutinin antigen dose was reduced in the adjuvanted arm (antigen-sparing design). \u2020This trial compared adjuvanted influenza vaccines and non-adjuvanted influenza vaccines from different manufacturers. Supplementary Table 2. Randomized controlled trials that reported seroprotection data This trial compared adjuvanted and non-adjuvanted vaccine formulations with unequal hemagglutinin antigen dose. The hemagglutinin antigen dose was reduced in the adjuvanted arm (antigen-sparing design). \u2020This trial compared adjuvanted influenza vaccines and non-adjuvanted influenza vaccines from different manufacturers. Supplementary Table 3. Randomized controlled trials that reported serious adverse events (SAEs)", "latex": null, "type": "table"}, "TABREF3": {"text": "Randomized controlled trials that reported neurological events *This trial compared adjuvanted and non-adjuvanted vaccine formulations with unequal hemagglutinin antigen dose. The hemagglutinin antigen dose was reduced in the adjuvanted arm (antigen-sparing design). \u2020This trial compared adjuvanted influenza vaccines and non-adjuvanted influenza vaccines from different manufacturers. SupplementaryTable 5. Randomized controlled trials that reported reactogenicity data", "latex": null, "type": "table"}, "TABREF4": {"text": "Table 5. Randomized controlled trials that reported reactogenicity data Study Study design Setting Vaccine strain Age of participants Vesikari 2009\u2020 (PIDJ) Vesikari 2009\u2020 (Vaccine) Waddington", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Non-adjuvanted </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>2010</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Pain </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>6-59 months </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>MF59-a</td><td>Non</td><td>after </td><td>\u00a0</td></tr><tr><td>rgueda</td><td>Phase 3 </td><td>Costa R</td><td>H1N1 </td><td>3-8 years </td><td>\u00a0</td><td>/Novart</td><td>1st and 2nd </td><td>\u00a0</td></tr><tr><td>011* </td><td>Open-label </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>/Novartis/15 \u00b5g </td><td>(n=54) </td><td>doses </td><td>Pain  </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>(n=56) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr></table></body></html>"}, "TABREF5": {"text": "Table 6. Summary of findings: certainty of evidence for effect outcomes Summary of findings: Oil-in-water emulsion adjuvanted influenza vaccine compared to non adjuvanted influenza vaccine in children Patient or population: children Setting: Poor response ( a <25% seroprotection after a single dose of nonadjuvanted influenza vaccine) Intervention: oil-in-water emulsion adjuvanted influenza vaccine Comparison: non adjuvanted influenza vaccine", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Outcomes </td><td>Anticipated absolute effects* Risk with non adjuvanted influenza vaccine </td><td>(95% CI) </td><td>Relative effect </td><td>\u2116 of participants (studies) </td><td>Certainty of the evidence (GRADE) Comments </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Risk with oil-in-water emulsion adjuvanted influenza vaccine </td><td>(95% CI) </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>vaccine efficacy assessed with RT-PCR test seroprotection assessed with: HI titer </td><td>22 per 1,000 </td><td>6 per 1,000 (3 to 10) </td><td>RR 0.26 (0.14 to 0.47) </td><td>4839 (3 RCTs) </td><td>\u2a01\u2a01\u2a01\u2a01 HIGH a,b </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>897 per 1,000 </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>(800 to 1,015) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>for H1N1 influenza virus after the first dose </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Rate ratio 4.6 </td><td>2308 </td><td>\u2a01\u2a01\u2a01\u25ef </td></tr><tr><td>195 per 1,000 </td><td>\u00a0</td><td>(4.1 to 5.2) </td><td>(4 RCTs) </td><td>MODERATE c,d,e,f </td></tr><tr><td>follow up: range 21 days to 28 days seroprotection assessed with: HI titer </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>944 per 1,000 </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>(800 to 1,123) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>for H3N2 influenza virus after the first dose </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Rate ratio 7.9 </td><td>2178 </td><td>\u2a01\u2a01\u2a01\u25ef </td></tr><tr><td>119 per 1,000 </td><td>\u00a0</td><td>(6.7 to 9.4) </td><td>(2 RCTs) </td><td>MODERATE d,e,f,g </td></tr><tr><td>follow up: range 21 days to 28 days seroprotection assessed with: HI titer for influenza B after the first dose </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>168 per 1,000 </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>(96 to 276) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>120 per 1,000 </td><td>\u00a0</td><td>Rate ratio 1.4 </td><td>2377 </td><td>\u2a01\u25ef\u25ef\u25ef </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>(0.8 to 2.3) </td><td>(3 RCTs) </td><td>VERY LOW e,g,h,i,j </td></tr><tr><td>follow up: range 21 days to 28 days seroprotection assessed with: Hi titer for influenza B after the second dose </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>1010 per 1,000 </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>(711 to 1,403) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Rate ratio 5.4 </td><td>2176 </td><td>\u2a01\u2a01\u2a01\u25ef </td></tr><tr><td>\u00a0</td><td>187 per 1,000 </td><td>\u00a0</td><td>(3.8 to 7.5) </td><td>(2 RCTs) </td><td>MODERATE d,e,f,k </td></tr><tr><td>follow up: range 21 days to 28 days *The risk in the intervention group </td><td>(and its 95% confidence interval) is based on the assumed risk in the comparison group and the </td><td>relative effect of the intervention (and its 95% </td></tr></table></body></html>"}, "TABREF6": {"text": "Table 7. Summary of findings: certainty of evidence for harm outcomes Summary of findings: Oil-in-water emulsion adjuvanted influenza vaccine compared to non adjuvanted influenza vaccine in children Patient or population: children Setting: Intervention: oil-in-water emulsion adjuvanted influenza vaccine Comparison: non adjuvanted influenza vaccine", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Outcomes </td><td>Anticipated absolute effects* Risk with non adjuvanted influenza vaccine </td><td>(95% CI) Risk with oil-in-water emulsion adjuvanted influenza vaccine </td><td>Relative effect (95% CI) </td><td>\u2116 of participants (studies) </td><td>Certainty of the evidence (GRADE) </td><td>Comments </td></tr><tr><td>Severe adverse events </td><td>47 per 1,000 </td><td>42 per 1,000 (33 to 52) </td><td>RR 0.9 (0.7 to 1.1) </td><td>25541 (15 RCTs) </td><td>\u2a01\u25ef\u25ef\u25ef VERY LOW a,b,c </td><td>\u00a0</td></tr><tr><td>Neurological events pain at the injection site after the first dose assessed with: yes or </td><td>0 per 1,000 </td><td>1 per 1,000 (0 to 2) </td><td>RR 1.4 (0.4 to 4.3) </td><td>20802 (15 RCTs) </td><td>\u2a01\u2a01\u25ef\u25ef LOW d,e </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>424 per 1,000 (391 to 489) </td><td>RR 1.3 </td><td>23184 </td><td>\u2a01\u2a01\u25ef\u25ef </td><td>\u00a0</td></tr><tr><td>no </td><td>326 per 1,000 </td><td>\u00a0</td><td>(1.2 to 1.5) </td><td>(14 RCTs) </td><td>LOW f,g </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>pain at the injection site after the second dose assessed with: yes or </td><td>\u00a0</td><td>299 per 1,000 </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>199 per 1,000 </td><td>(239 to 359) </td><td>RR 1.5 </td><td>12791 </td><td>\u2a01\u2a01\u25ef\u25ef </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>(1.2 to 1.8) </td><td>(13 RCTs) </td><td>LOW h,i </td><td>\u00a0</td></tr><tr><td>no </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>fever after the first dose assessed with: body </td><td>\u00a0</td><td>149 per 1,000 </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>93 per 1,000 </td><td>(130 to 167) </td><td>RR 1.6 </td><td>25359 </td><td>\u2a01\u2a01\u25ef\u25ef </td><td>\u00a0</td></tr><tr><td>temperature higher than 38 Celsius degree fever after the second </td><td>\u00a0</td><td>\u00a0</td><td>(1.4 to 1.8) </td><td>(14 RCTs) </td><td>LOW j,k </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>134 per 1,000 </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>dose </td><td>\u00a0</td><td>(107 to 169) </td><td>RR 1.5 </td><td>14719 </td><td>\u2a01\u2a01\u25ef\u25ef </td><td>\u00a0</td></tr><tr><td>assessed with: body </td><td>89 per 1,000 </td><td>\u00a0</td><td>(1.2 to 1.9) </td><td>(12 RCTs) </td><td>LOW l,m </td><td>\u00a0</td></tr><tr><td>temperature higher than 38 celsius degree </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>*The risk in the intervention group CI). </td><td>(and its 95% confidence interval) is based on the assumed risk in the comparison group and the </td><td>relative effect </td><td>of the intervention (and its 95% </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>CI: Confidence interval; RR: Risk ratio GRADE Working Group grades of evidence </td></tr></table></body></html>"}}, "back_matter": [{"text": "\u2a01\u2a01\u2a01\u25ef MODERATE d,e,f,k *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect Explanations a. Only 3 of the 18 included trials reported efficacy data. b. RR<0.5 c. Only 21 of the 26 included comparisons reported seroprotection rate data after the first-dose vaccination. d. The rate ratio was for poor response group. Meta-regression shows that between-trials heterogeneity in rate ratio was nearly all explained by serological response rates in the nonadjuvanted arm (see text for details). e. Measurement of immunogenicity was used as a surrogate for real-life protection against infection, disease and death f. RR >2.0 g. Only 12 of the 26 included comparisons reported seroprotection rate data after the first-dose vaccination. h. Test for heterogeneity p=0.05, I-square 67% i. The rate ratio was for poor response group j. Wide confidence interval k. Only 13 of the 26 included comparisons reported seroprotection rate data after the second-dose vaccination. \u2a01\u2a01\u25ef\u25ef LOW l,m *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect Explanations a. Only 15 of the 18 included trials reported rate data of SAEs during the follow-up period b. Test for heterogeneity P=0.02, I-square 50% c. Confidence interval 0.69-1.12 d. Only 15 of the 18 included trials reported rate data of neurological events during the follow-up period e. Wide confidence interval f. Only 19 of the 21 included comparisons reported rate data of pain after the first-dose vaccination g. Test for heterogeneity P<0.01, I-square 76% h. Only 17 of the 21 included comparisons reported rate data of pain after the second-dose vaccination i. Test for heterogeneity P<0.01, I-square 81% j. Only 20 of the 21 included comparisons reported rate data of fever after the first-dose vaccination k. Test for heterogeneity P=0.01, I-square 46%", "cite_spans": [], "ref_spans": [], "section": "annex"}]}